<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1870-7203</journal-id>
<journal-title><![CDATA[Acta médica Grupo Ángeles]]></journal-title>
<abbrev-journal-title><![CDATA[Acta méd. Grupo Ángeles]]></abbrev-journal-title>
<issn>1870-7203</issn>
<publisher>
<publisher-name><![CDATA[Grupo Ángeles, Servicios de Salud]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1870-72032021000100101</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Manifestaciones dermatológicas en amiloidosis secundaria a mieloma múltiple]]></article-title>
<article-title xml:lang="en"><![CDATA[Dermatological manifestations in amyloidosis secondary to multiple myeloma]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Figueroa Ramos]]></surname>
<given-names><![CDATA[Grecia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Álvarez Rivero]]></surname>
<given-names><![CDATA[Valeria]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gudiño Santos]]></surname>
<given-names><![CDATA[Ericka Fabiola]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Ángeles Metropolitano  ]]></institution>
<addr-line><![CDATA[CDMX ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Centro Dermatológico &#8220;Dr. Ladislao de la Pascua&#8221;  ]]></institution>
<addr-line><![CDATA[CDMX ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Centro Médico Nacional Siglo XXI Hospital de Especialidades ]]></institution>
<addr-line><![CDATA[CDMX ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2021</year>
</pub-date>
<volume>19</volume>
<numero>1</numero>
<fpage>101</fpage>
<lpage>107</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1870-72032021000100101&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1870-72032021000100101&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1870-72032021000100101&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen: El mieloma múltiple (MM) es una enfermedad maligna de células plasmáticas de linfocitos; B. Bluefarb estimó que aproximadamente el 15% de los pacientes con MM desarrollarán alguna forma de amiloidosis. El término amiloidosis hace referencia a la acumulación extracelular de un material amiloide, debido a un mal plegamiento de las proteínas autólogas. El subtipo de amiloidosis de cadenas ligeras lambda (AL) es el más común en amiloidosis cutánea asociada con MM. En México, la frecuencia de amiloidosis cutánea en la consulta dermatológica es de aproximadamente 0.5% y predomina en mujeres. La infiltración de tejido por estos depósitos de amiloide se produce de forma localizada o sistémica. Cuando la amiloidosis afecta la piel, puede ser como una manifestación de amiloidosis sistémica, o una amiloidosis cutánea localizada. Las enfermedades amiloides cutáneas pueden tener manifestaciones heterogéneas, dependiendo de la ubicación del depósito amiloide dentro de la dermis o la epidermis. El diagnóstico de amiloidosis se realiza histológicamente mediante la demostración del depósito de amiloide. El tratamiento de la amiloidosis va enfocado a cada tipo. Los pacientes con mieloma asociado con amiloidosis AL con afectación de la piel tienen el peor pronóstico.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract: Multiple myeloma (MM) is a malignant disease of plasma cells of B lymphocytes. Bluefarb estimated that approximately 15% of MM patients will develop some form of amyloidosis. The term amyloidosis refers to the extracellular accumulation of an amyloid material, due to a poor folding of autological proteins. The lambda light chain amyloidosis subtype is the most common in MM-associated cutaneous amyloidosis. In Mexico, the frequency of cutaneous amyloidosis in the dermatological consultation is only 0.5% and predominantly in women. Tissue infiltration by these amyloid residues occurs either locally or systemically. When amyloidosis affects the skin, it can be as a manifestation of systemic amyloidosis, or localized cutaneous amyloidosis. Cutaneous amyloid diseases can have heterogeneous manifestations, specific to the location of the amyloid deposit within the dermis or epidermis. The diagnosis of amyloidosis is made histologically by demonstrating the amyloid deposit. The treatment of amyloidosis is focused on each type. Patients with AL amyloidosis-associated myeloma with skin involvement have the worst prognosis.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Amiloidosis cutánea]]></kwd>
<kwd lng="es"><![CDATA[amiloidosis sistémica]]></kwd>
<kwd lng="es"><![CDATA[mieloma múltiple]]></kwd>
<kwd lng="en"><![CDATA[Cutaneous amyloidosis]]></kwd>
<kwd lng="en"><![CDATA[systemic amyloidosis]]></kwd>
<kwd lng="en"><![CDATA[multiple myeloma]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bergstrom]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kotb]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Louzada]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Sutherland]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Tavoularis]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Venner]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consensus guidelines on the diagnosis of multiple myeloma and related disorders: recommendations of the myeloma canada research network consensus guideline consortium]]></article-title>
<collab>Myeloma Canada Research Network Consensus Guideline Consortium</collab>
<source><![CDATA[Clin Lymphoma Myeloma Leuk]]></source>
<year>2020</year>
<volume>20</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>e352-67</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kois]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Sexton]]></surname>
<given-names><![CDATA[FM]]></given-names>
</name>
<name>
<surname><![CDATA[Lookingbill]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cutaneous manifestations of multiple myeloma]]></article-title>
<source><![CDATA[Arch Dermatol]]></source>
<year>1991</year>
<volume>127</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>69-74</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Navarrete]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Novales]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Guarneros]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cortés]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multiple myeloma and systemic amyloidosis]]></article-title>
<source><![CDATA[Int J Dermatol]]></source>
<year>2008</year>
<volume>47</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>165-7</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chuang]]></surname>
<given-names><![CDATA[YY]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[DD]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[YJ]]></given-names>
</name>
<name>
<surname><![CDATA[Tanaka]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[YT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Characteristic dermoscopic features of primary cutaneous amyloidosis: a study of 35 cases]]></article-title>
<source><![CDATA[Br J Dermatol]]></source>
<year>2012</year>
<volume>167</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>548-54</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arenas]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Dermatología. Atlas, diagnóstico y tratamiento]]></source>
<year>2015</year>
<edition>6</edition>
<publisher-loc><![CDATA[Ciudad de México ]]></publisher-loc>
<publisher-name><![CDATA[McGraw Hill Education]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[OC]]></given-names>
</name>
<name>
<surname><![CDATA[Wechalekar]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systemic amyloidosis: moving into the spotlight]]></article-title>
<source><![CDATA[Leukemia]]></source>
<year>2020</year>
<volume>34</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1215-28</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kang]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Amagai]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bruckner]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Enk]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Margolis]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[McMichael]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Fitzpatrick&#8217;s dermatology]]></source>
<year>2019</year>
<edition>9</edition>
<publisher-loc><![CDATA[Nueva York ]]></publisher-loc>
<publisher-name><![CDATA[McGraw Hill Education]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lavorato]]></surname>
<given-names><![CDATA[FG]]></given-names>
</name>
<name>
<surname><![CDATA[Alves Mde]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Maceira]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Unterstell]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Serpa]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Azulay-Abulafia]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primary systemic amyloidosis, acquired cutis laxa and cutaneous mucinosis in a patient with multiple myeloma]]></article-title>
<source><![CDATA[An Bras Dermatol]]></source>
<year>2013</year>
<volume>88</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>32-5</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Medina-Castillo]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Quiroz-Mejía]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Caliope-Carrera]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Paredes-Ceballos]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Aranda-Díaz]]></surname>
<given-names><![CDATA[EI]]></given-names>
</name>
<name>
<surname><![CDATA[Barrios-González]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Amiloidosis sistémica]]></article-title>
<source><![CDATA[Dermatol Rev Mex]]></source>
<year>2015</year>
<volume>59</volume>
<page-range>208-18</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oliveira]]></surname>
<given-names><![CDATA[EV]]></given-names>
</name>
<name>
<surname><![CDATA[Pozetti]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Pozetti]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Antonio]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Michalany]]></surname>
<given-names><![CDATA[NS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primary systemic amyloidosis associated with multiple myeloma]]></article-title>
<source><![CDATA[An Bras Dermatol]]></source>
<year>2012</year>
<volume>87</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>119-22</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leung]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Nasr]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Sethi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[How I treat amyloidosis: the importance of accurate diagnosis and amyloid typing]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2012</year>
<volume>120</volume>
<numero>16</numero>
<issue>16</issue>
<page-range>3206-13</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rubinow]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Skin involvement in generalized amyloidosis. A study of clinically involved and uninvolved skin in 50 patients with primary and secondary amyloidosis]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>1978</year>
<volume>88</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>781-5</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saúl]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Saúl. Lecciones de dermatología]]></source>
<year>2015</year>
<edition>16</edition>
<publisher-loc><![CDATA[Ciudad de México ]]></publisher-loc>
<publisher-name><![CDATA[McGraw Hill Education]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caruana]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[McCusker]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Harper]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bilsland]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Curious facial plaque diagnosed as nodular primary localised cutaneous amyloidosis]]></article-title>
<source><![CDATA[BMJ Case Rep]]></source>
<year>2019</year>
<volume>12</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Andrei]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cutaneous light chain amyloidosis with multiple myeloma: a concise review]]></article-title>
<source><![CDATA[Hematol Oncol Stem Cell Ther]]></source>
<year>2019</year>
<volume>12</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>71-81</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moatamedi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Derakhshan]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Images of the month 4: cutaneous amyloidosis: a clinical challenge]]></article-title>
<source><![CDATA[Clin Med (Lond)]]></source>
<year>2019</year>
<volume>19</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>418-20</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dupont]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Martins Souza]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
<name>
<surname><![CDATA[Damiani]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Boff]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cutaneous nodular amyloidosis: a disfiguring aspect of the face]]></article-title>
<source><![CDATA[Am J Dermatopathol]]></source>
<year>2019</year>
<volume>41</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>945-7</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kaliyadan]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Alkhateeb]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kuruvilla]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Swaroop]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Alabdulsalam]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dermoscopy of primary cutaneous amyloidosis in skin of color]]></article-title>
<source><![CDATA[Dermatol Pract Concept]]></source>
<year>2019</year>
<volume>9</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>232-4</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Weidner]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Illing]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Elsner]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primary localized cutaneous amyloidosis: a systematic treatment review]]></article-title>
<source><![CDATA[Am J Clin Dermatol]]></source>
<year>2017</year>
<volume>18</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>629-42</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Penner]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
<name>
<surname><![CDATA[Muller]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Head and neck amyloidosis: a clinicopathologic study of 15 cases]]></article-title>
<source><![CDATA[Oral Oncol]]></source>
<year>2006</year>
<volume>42</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>421-9</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rysavá]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[AL amyloidosis: advances in diagnostics and treatment]]></article-title>
<source><![CDATA[Nephrol Dial Transplant]]></source>
<year>2019</year>
<volume>34</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1460-6</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Venner]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Lane]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Foard]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Rannigan]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Gibbs]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Pinney]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2012</year>
<volume>119</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>4387-90</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kaufman]]></surname>
<given-names><![CDATA[GP]]></given-names>
</name>
<name>
<surname><![CDATA[Schrier]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Lafayette]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Arai]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Witteles]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Liedtke]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2017</year>
<volume>130</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>900-2</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
